TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07024277: A Phase II Study Evaluating the Preliminary Efficacy and Safety of ZG006 in Participants With Metastatic Neuroendocrine Prostate Cancer

Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$14,784,000

Rescue Site Savings

+$9,748,200

Unlock Full NCT07024277 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07024277 Rescue Dossier →